Hyun Soo Seo

Hyun Soo Seo

Auto-generated profile, based on publicly available information

Hyun Soo Seo

Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LNLe Phuong Nguyen
Le Phuong Nguyen
CPChul Soon Park
Chul Soon Park
NPNaina Pinto
Naina Pinto
HLHyunsook Lee
Hyunsook Lee
HSHyun Soo Seo
Hyun Soo Seo
DYDongeun Yong
Dongeun Yong
The siderophore–antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and meropenem were measured using the agar dilution method. Whole genome sequencing was performed using Illumina and the resistome was analyzed. LCB10-0200 displayed stronger activity than the comparator drugs in meropenem-resistant E. coli and K. pneumoniae, and the addition of AVI enhanced the LCB10-0200 activity to MIC ≤ 0.12 mg/L for 90.5% of isolates. In contrast, whereas LCB10-0200 alone showed potent activity against meropenem-resistant A. baumannii and P. aeruginosa at MIC ≤ 4 mg/L for 84.3% of isolates, the combination with AVI did not improve its activity. LCB10-0200/AVI was active against CTX-M-, SHV-, CMY-, and KPC- producing E. coli and K. pneumoniae, while LCB10-0200 alone was active against ADC-, OXA-, and VIM- producing A. baumannii and P. aeruginosa. Both LCB10-0200 and LCB10-0200/AVI displayed low activity against IMP- and NDM- producing strains. LCB10-0200 alone exhibited strong activity against selected strains. The addition of AVI significantly increased LCB10-0200 activity against carbapenem-resistant E. coli, K. pneumoniae.

1 July 2021 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
HSHyun Soo Seo
Hyun Soo Seo
HCHyung Sun Chin
Hyung Sun Chin
YKYeon-Hee Kim
Yeon-Hee Kim
HMHye Su Moon
Hye Su Moon
KKKyungnam Kim
Kyungnam Kim
PHPh.D.
Ph.D.
Hyun Soo Seo, M.S., Hyung Sun Chin, B.S.N., Yeon-Hee Kim, M.S., Hye Su Moon, B.S., Kyungnam Kim, B.S., Le Phuong Nguyen, M.D., and Dongeun Yong, M.D., Ph.D.. Ann Lab Med 2021;41:424-8. https://doi.org/10.3343/alm.2021.41.4.424